The company
Xeris Biopharma Holdings, Inc.
XERS · Nasdaq
XERS stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 15 weeks. It is 37.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 15 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $8.9M
- Officials’ trades on record
- 0
- Institutions holding
- 226 (+11)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Beth HechtOfficer | sold | 16,666at $9.41 | 1 Oct 2026filed 2 Oct 2026 |
| Kevin McCullochOfficer | sold | 15,000at $9.41 | 1 Oct 2026filed 2 Oct 2026 |
| Steven PieperOfficer | sold | 5,000at $9.41 | 1 Oct 2026filed 2 Oct 2026 |
| Kevin McCullochOfficer | sold | 25,000at $10.00 | 28 Sep 2026filed 29 Sep 2026 |
| Beth HechtOfficer | sold | 16,666at $8.49 | 1 Sep 2026filed 1 Sep 2026 |
| Steven PieperOfficer | sold | 5,000at $8.50 | 1 Sep 2026filed 1 Sep 2026 |
| Kevin McCullochOfficer | sold | 15,000at $8.49 | 1 Sep 2026filed 1 Sep 2026 |
| Steven PieperOfficer | sold | 5,000at $8.50 | 12 Aug 2026filed 12 Aug 2026 |
| Beth HechtOfficer | sold | 16,666at $8.01 | 3 Aug 2026filed 4 Aug 2026 |
| Kevin McCullochOfficer | sold | 15,000at $8.02 | 3 Aug 2026filed 4 Aug 2026 |
| Steven PieperOfficer | sold | 27,600at $8.52 | 7 Jul 2026filed 7 Jul 2026 |
| Steven PieperOfficer | sold | 17,400at $8.50 | 6 Jul 2026filed 7 Jul 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 14,525,539$115.0M | +1,579,754+12.2% |
| D. E. Shaw & Co., Inc.added · filed 14 Aug 2026 | 7,804,758$61.8M | +15,947+0.2% |
| VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026 | 7,340,229$58.1M | +7,340,229 |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,821,566$38.2M | +163,392+3.5% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 4,718,183$37.4M | +427,554+10.0% |
| Nuveen, LLCadded · filed 11 Aug 2026 | 4,385,141$34.7M | +1,468,543+50.4% |
| Rosalind Advisors, Inc.reduced · filed 14 Aug 2026 | 2,908,981$23.0M | -322,719−10.0% |
| Qube Research & Technologies Ltdreduced · filed 14 Aug 2026 | 2,893,749$22.9M | -1,220,676−29.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLCnew · filed 13 Aug 2026 | 2,626,208$20.8M | +2,626,208 |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 2,365,103$18.7M | +193,749+8.9% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.